Results 191 to 200 of about 12,575 (207)

Simultaneous Pharmacogenetics-Based Population Pharmacokinetic Analysis of Darunavir and Ritonavir in HIV-Infected Patients

Clinical Pharmacokinetics, 2013
JOSÉ Moltó, George Xinarianos, Cristina Miranda   +2 more
exaly  

Body fat distribution in HIV‐infected patients treated for 96 weeks with darunavir/ritonavir monotherapy versus darunavir/ritonavir plus nucleoside reverse transcriptase inhibitors: the MONOI‐ANRS136 Substudy

HIV Medicine, 2012
Philippe Flandre, J L Meynard, L Slama
exaly  

Darunavir/raltegravir

Reactions Weekly, 2018
openaire   +1 more source

Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV

Bioorganic and Medicinal Chemistry, 2007
Arun K Ghosh, Hiroaki Mitsuya
exaly  

Darunavir/ritonavir

Reactions Weekly, 2013
openaire   +2 more sources

Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study

Journal of Antimicrobial Chemotherapy, 2012
Laurence Morand-Joubert, André Cabie, J L Meynard   +2 more
exaly  

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

Lancet, The, 2007
Jean-Christophe Goffard, Adriano Lazzarin, Richard Haubrich   +2 more
exaly  

Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV‐1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily

HIV Medicine, 2014
S Yasin, Thomas N Kakuda
exaly  

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial

Lancet, The, 2007
JOSÉ Valdez Madruga, Daniel Berger, Fredy Suter   +2 more
exaly  

Cobicistat/darunavir

Reactions Weekly, 2017
openaire   +1 more source